|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||81.12 / 121.75|
Canaccord is bullish on Edwards Lifescience stock.
Here are Thursday's top research calls, including downgrades for CVS, Edwards Lifesciences and Qorvo, and an upgrade for Tesoro.
However, more consolidation may be needed before the uptrend resumes.
The small business survey signals more building, more hiring, and more buying, Jim Cramer says.
Still, volume and positive money flow will need to improve to sustain a breakout move in the name.
The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.
As the dominant player in the transcatheter aortic valve replacement market, Edwards doesn't 'need' large deals.
Insiders at these companies have been scooping up shares of their own stock lately.
Cramer says he likes Twilio for the long term and is taking Nvidia over Himax.
When it comes to growth, what's good for the American people may also now be good for stocks, Cramer says.
Additionally, Edwards Board Approves New $1 Billion Share Repurchase Program
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Jim Cramer says UVE is not bad, and he likes AIG and ALL as well.
Jim Cramer names companies with credibility, like NXPI and AAPL, and those that don't have it, including FIT.